Literature DB >> 33669021

P16 and HPV Genotype Significance in HPV-Associated Cervical Cancer-A Large Cohort of Two Tertiary Referral Centers.

Sara da Mata1,2, Joana Ferreira1,2, Inmaculada Nicolás3, Susana Esteves4, Gonçalo Esteves5, Sofia Lérias1, Fernanda Silva2, Adela Saco6, Daniela Cochicho7, Mário Cunha7, Marta Del Pino3, Jaume Ordi6,8, Ana Félix1,2.   

Abstract

The expression of p16 is a good surrogate of human papillomavirus (HPV) infection in HPV-associated cancers. The significance of p16 expression, HPV genotype and genera in the outcome of patients with HPV-associated cervical cancer (CC) is unclear. Our aim is to ascertain the prognostic significance of these factors. Data from 348 patients (median age: 47.5 years old) with CC, diagnosed in two referral centers, were retrospectively collected. Advanced disease (FIGO2018 IB2-IV) was present in 68% of patients. A single HPV genotype was identified in 82.8% of patients. The most common HPVs were HPV16 (69%) and HPV18 (14%). HPV genera reflected this distribution. HPV16 tumors presented at an earlier stage. P16 was negative in 18 cases (5.2%), 83.3% of which were squamous cell carcinomas. These cases occurred in older patients who tended to have advanced disease. In the univariate analysis, HPV16 (HR: 0.58; p = 0.0198), α-9 genera (HR: 0.37; p = 0.0106) and p16 overexpression (HR: 0.54; p = 0.032) were associated with better survival. HPV16 (HR: 0.63; p = 0.0174) and α-9 genera (HR: 0.57; p = 0.0286) were associated with less relapse. In the multivariate analysis, only the International Federation of Gynecology and Obstetrics (FIGO) stage retained an independent prognostic value. HPV16, α-9 genera and p16 overexpression were associated with better survival, although not as independent prognostic factors. Patients with p16-negative HPV-associated CC were older, presented with advanced disease and had worse prognosis.

Entities:  

Keywords:  HPV; cervical cancer; p16 expression

Mesh:

Substances:

Year:  2021        PMID: 33669021      PMCID: PMC7956391          DOI: 10.3390/ijms22052294

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  44 in total

1.  Clinical and prognosis value of the CIMP status combined with MLH1 or p16 INK4a methylation in colorectal cancer.

Authors:  Amana Saadallah-Kallel; Rania Abdelmaksoud-Dammak; Mouna Triki; Slim Charfi; Abdelmajid Khabir; Tahia Sallemi-Boudawara; Raja Mokdad-Gargouri
Journal:  Med Oncol       Date:  2017-07-20       Impact factor: 3.064

2.  Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome.

Authors:  Yuxin Liu; Mahfood Alqatari; Kieran Sultan; Fei Ye; Dana Gao; Keith Sigel; David Zhang; Tamara Kalir
Journal:  Hum Pathol       Date:  2017-07-11       Impact factor: 3.466

3.  "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1,594 cases".

Authors:  Natalia Rakislova; Omar Clavero; Laia Alemany; Adela Saco; Beatriz Quirós; Belen Lloveras; Maria Alejo; Michael Pawlita; Wim Quint; Marta Del Pino; Silvia de Sanjose; Jaume Ordi
Journal:  Int J Cancer       Date:  2017-08-31       Impact factor: 7.396

4.  HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy.

Authors:  Woo Dae Kang; Cheol Hong Kim; Moon Kyoung Cho; Jong Woon Kim; Hye Yon Cho; Yoon Ha Kim; Ho Sun Choi; Seok Mo Kim
Journal:  Gynecol Oncol       Date:  2011-02-21       Impact factor: 5.482

5.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Authors:  Michelle J Khan; Philip E Castle; Attila T Lorincz; Sholom Wacholder; Mark Sherman; David R Scott; Brenda B Rush; Andrew G Glass; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

6.  Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

Authors:  Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Anna Gillio-Tos; Laura De Marco; Paolo Giorgi-Rossi; Giovanni Pontenani; Stefano Rosso; Cristina Sani; Catia Sintoni; Nereo Segnan; Manuel Zorzi; Jack Cuzick; Raffaella Rizzolo; Guglielmo Ronco
Journal:  Lancet Oncol       Date:  2008-09-08       Impact factor: 41.316

7.  [Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix].

Authors:  Jaume Ordi; Lluís M Puig-Tintoré; Aureli Torné; Sergi Sanz; Roser Esteve; Cleofé Romagosa; Antonio Cardesa
Journal:  Med Clin (Barc)       Date:  2003-10-11       Impact factor: 1.725

8.  Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.

Authors:  Gun Oh Chong; Yoon Hee Lee; Hyung Soo Han; Hyun Jung Lee; Ji Young Park; Dae Gy Hong; Yoon Soon Lee; Young Lae Cho
Journal:  Gynecol Oncol       Date:  2017-11-15       Impact factor: 5.482

9.  Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.

Authors:  Ruth Holm; Irene Kraus; Hanne Skomedal; Anita Langerød; Gunnar B Kristensen; Heidi Lyng
Journal:  Open Virol J       Date:  2008-10-24

10.  Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy.

Authors:  Malin Kaliff; Bengt Sorbe; Louise Bohr Mordhorst; Gisela Helenius; Mats G Karlsson; Gabriella Lillsunde-Larsson
Journal:  Oncotarget       Date:  2018-04-10
View more
  3 in total

1.  HPV Status and Individual Characteristics of Human Papillomavirus Infection as Predictors for Clinical Outcome of Locally Advanced Cervical Cancer.

Authors:  Liana Mkrtchian; Irina Zamulaeva; Liudmila Krikunova; Valentina Kiseleva; Olga Matchuk; Liubov Liubina; Gunel Kulieva; Sergey Ivanov; Andrey Kaprin
Journal:  J Pers Med       Date:  2021-05-27

Review 2.  Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.

Authors:  Daria A Haręża; Jacek R Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

3.  Mutational Signature and Integrative Genomic Analysis of Human Papillomavirus-Associated Penile Squamous Cell Carcinomas from Latin American Patients.

Authors:  Luisa Matos Canto; Jenilson Mota da Silva; Patrícia Valèria Castelo-Branco; Ingrid Monteiro da Silva; Leudivan Nogueira; Carlos Eduardo Fonseca-Alves; André Khayat; Alexander Birbrair; Silma Regina Pereira
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.